We have initiated a Phase II trial of GRNVAC1 in patients with acute myelogenous leukemia (AML) in complete remission. The primary objective of this new Phase II study is to evaluate the safety and feasibility of a prime-boost vaccination regimen that extends the duration of telomerase immunity. Secondary objectives are to evaluate the immune response to GRNVAC1 and to explore the effects of vaccination on minimal residual disease and relapse rates.
This trial is now closed to patient enrollment, but is active at the following sites:
Washington University
Siteman Cancer Center
St. Louis, MO
Liz Procknow
Telephone: 314-454-5096
University of Texas Southwestern
Harold C. Simmons Comprehensive Cancer Center
Dallas, TX
Tracee Rainey, RN
Telephone: 214-648-5102
The Ohio State University Medical Center
Columbus, OH
Anders Lindquist
Telephone: 614-293-6541
Emory University School of Medicine
Winship Cancer Institute
Atlanta, GA
Mersiha Torlak
Telephone: 404-778-4582
Loyola University Medical Center
Maywood, IL
Sandra Zakrzewski
Telephone: 708-327-2831
University of Nebraska Medical Center
Omaha, NE
Rose Hoyt
Telephone: 402-559-4810
For a brief synopsis of the GRNVAC1 trial, visit the U.S. National Library of Medicine website at http://www.clinicaltrials.gov
